新型抗肿瘤药物不良反应调查分析

发布时间：2018-07-01 14:56

  本文选题：抗肿瘤药物 + 不良反应　； 参考：《山东大学》2014年硕士论文

【摘要】：目的：探讨和分析新型抗肿瘤药物不良反应现状 方法：本文随机选取温州医科大学第一附属医院2011年7月到2013年10月进行化疗的肿瘤患者病例500例,其中男250例,女250例,年龄范围为10-85岁,中位年龄48岁,采用序号顺序逐一选择,其病理均经病理组织学证实,且病人均进行了药物化疗；疾病分类,以原发肿瘤为准。共涉及21种肿瘤病种,50种肿瘤药物,51种化疗方案。 结果：(1)采用联合FOLFIRI或mIFL方案治疗12例,联合氟尿嘧啶类治疗12例。同时比较单一性mFOLFOX方案治疗24例。Bev(贝伐珠单抗)治疗0.6-29.2个月,中位治疗3.5个月。生存期计算从开始治疗之日起至死亡或末次随访之日止。其不良反应效果如表3-2,采用联合治疗方案的患者其不良反应显著减少(P0.05)。由此说明Bev(贝伐珠单抗)联合不同化疗方案治疗直肠癌疗效肯定,不良反应可以耐受,且未加重化疗的不良反应。 (2)对于乳腺癌患者的治疗采用依决洛单抗联合曲妥珠单抗(方案A)与Pertuzumab(帕妥珠单抗)联合依决洛单抗(方案B)的治疗方案比较。其不良反应效果如表3-3,采用方案A的患者其不良反应显著减少(P0.05),由此依决洛单抗联合曲妥珠单抗方案治疗优于Pertuzumab(帕妥珠单抗)联合依决洛单抗方案,能够更好地降低患者的不良反应发生率。 (3)随着年龄的增加,Ⅲ-Ⅳ级恶心、呕吐、腹泻发生率明显增加,50岁-70岁是不良反应发生率高峰,病人更易发生药物不良反应,但70岁以后不良反应发生率又有所下降。 结论：抗肿瘤药物不良反应发生率高、毒副作用大,一般为剂量限制性毒性。但在有效的抗肿瘤治疗过程中,化疗必须规范、足量、足疗程,不得随意减量或终止或延长化疗时间,所以,既要取得最佳疗效,又需尽可能降低不良反应,施行个体化用药。
[Abstract]:Objective: to investigate and analyze the current status of adverse drug reactions of new antitumor drugs: a total of 500 cancer patients, including 250 males, were selected randomly from July 2011 to October 2013 in the first affiliated Hospital of Wenzhou Medical University. 250 cases of female, aged 10-85 years, median age of 48 years, were selected one by serial number sequence, their pathology were confirmed by histopathology, and all patients underwent drug chemotherapy, and the classification of diseases was based on the primary tumor. A total of 51 chemotherapeutic regimens involving 21 kinds of oncology and 50 kinds of tumor drugs were involved. Results: (1) 12 cases were treated with FOLFIRI or mIFL regimen and 12 cases were treated with fluorouracil. At the same time, the single mFOLFOX regimen was compared in 24 cases. Bev (bevacizumab) was treated for 0.6-29.2 months, and the median treatment was 3.5 months. Survival was calculated from the beginning of treatment to the date of death or last follow-up. The adverse effects were as shown in Table 3-2, and the adverse reactions of patients with combined therapy were significantly reduced (P0.05). It is concluded that Bev (bevacizumab) combined with different chemotherapy regimens is effective in the treatment of rectal cancer, and the adverse reactions can be tolerated. The adverse effects of chemotherapy were not aggravated. (2) the treatment of breast cancer patients was compared with that of Pertuzumab and Pertuzumab combined with Etolomab (option B). The adverse effects of the treatment were as shown in Table 3-3. The adverse reactions of patients with regimen A were significantly reduced (P0.05), so that the combination of Etolomab and tritozumab was better than that of Pertuzumab combined with Evolumab. (3) with the increase of age, the incidence of grade 鈪，

本文编号：2088143